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Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of
CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational
Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune
checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.Recent clinical successes of immuno-
therapy for cancer support a model
whereby T cell responses are generated
against tumor antigens only to be
thwarted by negative regulatory mecha-
nisms that comprise the tumor microenvi-
ronment (Postow et al., 2015). Indeed, it
is clear that, for some patients, check-
point blockade directed against PD-1
and CTLA-4 is able to unleash T cells
capable of promoting durable tumor
regression. Recently, Hatfield et al.
(2015) presented data accentuating the
role of the hypoxia-adenosine-A2aR
axis as a checkpoint in thwarting anti-
tumor immune responses. For checkpoint
blockade, they employ oxygen.
Over the past two decades, a multitude
of studies have demonstrated the critical
role of extracellular adenosine as an
immunoregulatory agent to prevent the
development of over-exuberant immune
responses (Young et al., 2014). As an im-
mune response develops, against patho-
genic invasion for example, increased
cellular turnover and hypoxia promote
the production and release of large
amounts of adenosine into the local
microenvironment (Figure 1). Signaling
through the A2a and A2b adenosine re-
ceptors (receptors that are broadly ex-
pressed on immune cells), adenosine
triggers a pleiotropic cascade of immuno-
suppressive effects, dampening the in-
flammatory response and protecting
surrounding tissues from immune-medi-
ated damage. Increasing hypoxia in in-
flamed tissues triggers the accumulation
of adenosine by depleting intracellularATP, increasing intracellular AMP, in-
creasing expression of 50-nucleotidase,
and, through hypoxia-inducible factor-1a
(HIF-1a) activity, inhibiting adenosine ki-
nase activity (Decking et al., 1997; Sitkov-
sky, 2009). The increased activity of
HIF-1a in hypoxic conditions also drives
the expression of the CD73 and CD39
transmembrane ectonucleotidases that
work in tandem to degrade extracellular
ATP to adenosine (Young et al., 2014). As
the adenosine concentration increases in
the extracellular environment, increased
signaling through Gs-protein-coupled re-
ceptors (A2a and A2b) produces an eleva-
tion in intracellular cAMP, ultimately
suppressing the release of inflammatory
mediators and enhancing the expression
of immunosuppressive factors.
In their article recently published in
Science Translational Medicine, Hatfield
et al. (2015) not only hypothesized that
the hypoxia-adenosine-A2aR axis was
acting as a ‘‘checkpoint’’ to inhibit anti-
tumor immunity, but, more provocatively,
that they could overcome this inhibition by
using supplemental oxygen to produce
hyperoxia in mice. To this end, multiple
pulmonary tumors were established by
the intravenous injection of B16 mela-
noma or MCA205 fibrosarcoma tumor
cells. By simply allowing mice to breath
60% oxygen, they were able to demon-
strate a marked decrease in tumor size
as well as a marked increase in overall
survival when compared to mice breath-
ing ambient air. Notably, the anti-tumor
responses were completely abrogated in
gc/Rag-2/ mice that are deficient in TCancer Celand NK cells, thus demonstrating the
requirement of immune effector cells to
enact the antitumor response. With the
use of monoclonal antibodies to deplete
CD4+, CD8+, and NK cells, they demon-
strated further that, while the effect of hy-
peroxic breathing on tumor regression
was greatly attenuated in the absence of
CD4+ and CD8 T+ cells, the effect was
completely abrogated after the depletion
of the NK cell population. Importantly,
the authors also showed that, in contrast
to wild-type mice, hyperoxia had no
detectable effect on enhancing anti-
tumor immunity further in A2aR null
mice. This latter finding implicates a role
for the A2aR in mediating the hypoxia-
induced immunosuppression. Lastly,
administration of a reactive oxygen spe-
cies (ROS) scavenger had no effect on
the tumor response, indicating that ROS
and related cytotoxicity did not play a
meaningful role in the observed tumor
response.
Interestingly, altering the oxygen ten-
sion of the tumor microenvironment also
had an effect on T cell trafficking. First,
through immunohistochemical staining
of tumor tissue sections, the authors
were able to demonstrate that CD8+
T cells preferentially localized to non-hyp-
oxic regions within a particular tumor.
Second, by using an in vivomarker of hyp-
oxia, they demonstrated that hyperoxic
respiration decreases CD8+ and CD4+
T cell exposure to hypoxic microenviron-
ments. Third, the authors observed a dra-
matic increase in recruitment of CD8+
T cells to established MCA205 tumors inl 27, April 13, 2015 ª2015 Elsevier Inc. 435
Figure 1. The Hypoxia-Adenosinergic Pathway in
Immune Regulation
Partially through stabilization of HIF-1a, hypoxia in inflamed and
cancerous tissues drives the intracellular accumulation of
adenosine by causing decreased ATP and adenosine kinase
(AK) activity as well as increasing intracellular AMP and
50-nucleotidase activity (50N). Additionally, HIF-1a activity
drives increased expression of the 50-ectonucleotidases
CD39 and CD73, which are transmembrane proteins that cata-
lyze the enzymatic breakdown of ATP to adenosine. Both of
these mechanisms lead to significant elevation of extracellular
adenosine concentrations in the microenvironment. Signaling
through two Gs-protein-coupled adenosine receptors (A2aR
and A2bR), adenosine triggers an increase in the intracellular
signaling molecule cyclic AMP (cAMP). Within immune effector
cells such as cytotoxic T cells and NK cells, cAMP causes a
buildup of a range of immunosuppressive factors (TGF-b,
IL-10, CTLA-4, PD-1, Galectin-1, FoxP3), as well as the down-
regulation of key effector molecules (IL-2, INF-g, TNF-a, per-
forin, IL-12, MIP1a) involved in an active immune response.
A2aR, adenosine A2a receptor; A2bR, adenosine A2b receptor;
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; FoxP3,
forkhead box P3; HIF1-a, hypoxia inducible factor-1a; INFg,
interferon-g; IL-2, interleukin-2; IL-10, interleukin-10; IL-12,
interleukin-12; MIP1a, macrophage inflammatory protein 1a;
PD-1, programmed cell death protein 1; TGF-b, transforming
growth factor-b; TNFa, tumor necrosis factor-a.
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Importantly, when evaluated for
CD69 and CD44 expression by
flow cytometry, these CD8+ T cells
were significantly more highly acti-
vated than those isolated from
mice exposed only to ambient O2.
The increased CD8+ T cell traf-
ficking was supported by the
change in expression of over 50 cy-
tokines, chemokines, and chemo-
kine receptors. These findings
were extended by showing that the
number of adoptively transferred,
CFSE-labeled T cells that traffic to
established tumors was 3-fold
higher per unit area in mice under-
going hyperoxic respiration than
control mice. Furthermore, hyper-
oxia resulted in a decrease in the
percentage of T regulatory cells
in the tumor microenvironment,
decrease in Foxp3 expression,
decrease in CD39 and CD73
expression on the T regulatory cells,
as well as a decrease in the expres-
sion of CTLA-4 on the T regulatory
cells. While it is thought that tumor
infiltrating T regulatory cells easily
adapt to the tumor microenviron-
ment, it appeared as though altering
the oxygen tension in the tumor dis-
rupted this adaptive process.
Overall, these studies have
potentially important implications
for the further development of
immunotherapy for cancer. First,
they confirm and provide insightful
details concerning the role of
hypoxia, adenosine, and the A2aR
in inhibiting anti-tumor immune
responses. To this end, these find-
ings support the development of
A2aR antagonists and CD73 inhibi-
tors as novel agents to enhance
immunotherapy. Second, these
observations immediately lend
themselves to devising novel and
synergistic clinical approaches.
The simplicity of oxygen therapyas a means of enhancing immunotherapy
is appealing. Yes, persistent hyperoxia
can lead to tissue damage both in the
lungs and liver (Kallet and Matthay,
2013; Zangl et al., 2014). Thus, reproduc-436 Cancer Cell 27, April 13, 2015 ª2015 Elsing these findings in humans in a way that
limits hyperoxia-induced injury will be
challenging. However, one can imagine
sequencing oxygen therapy with anti-
PD-1, anti-CTLA-4, or even A2aRevier Inc.blockade as a means of making
the tumor microenvironment more
hospitable for immune-mediated
tumor destruction. As higher popu-
lations of intratumoral CD8+ cells
have been correlated to better
clinical responses to PD-1 check-
point blockade (Tumeh et al.,
2014), the observation that hyper-
oxia can increase CD8+ T cells and
decrease Foxp3+ T regulatory
T cells within the tumor portends
well for combining oxygen and
other modalities. Along these lines,
given the pivotal role of oxygen
in regulating both tumor and im-
mune cell metabolism and function
(Palazon et al., 2014; Zeng et al.,
2015), increasing the oxygen ten-
sion within the tumor microenviron-
ment might prove to be a simple
means of simultaneously damp-
ening multiple immune regulatory
checkpoints.
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